Showing results (41-50 of 107) with videos related to

Sort By:
Pageof 11
Investigational New Drugs|August 23, 2018
A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphomaTycel Phillips, Paul M Barr, Steven I Park, et al.
Hemasphere|July 9, 2026
Efficacy of high-frequency low-dose rituximab and acalabrutinib in chronic lymphocytic leukemiaCharles C Chu, Clare B Heffernan, Nydia C Jaimes-Delgadillo, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 22, 2016
Late Relapses After High-dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With Diffuse Large B-cell Lymphoma in the Rituximab EraBradley D Hunter, Megan Herr, Philip J Meacham, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 7, 2025
Feasibility of Bruton's Tyrosine Kinase Inhibitor Discontinuation in Chronic Lymphocytic Leukemia: The Patient PerspectiveDeborah M Stephens, Chris Stewart, Liza Avruch, et al.
Blood|July 30, 2025
Final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment for CLL/SLLJan A Burger, Paul M Barr, Tadeusz Robak, et al.
Leukemia Research|April 1, 2023
Rituximab induced cytokine release with high serum IP-10 (CXCL10) concentrations is associated with infusion reactionsJeremiah E Moore, Paige C Bloom, Charles C Chu, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 29, 2011
Spontaneous autologous graft-versus-host disease in plasma cell myeloma autograft recipients: flow cytometric analysis of hematopoietic progenitor cell graftsHillard M Lazarus, Scott R Sommers, Lisa M Arfons, et al.
British Journal of Haematology|April 12, 2017
Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinibJeffrey A Jones, Peter Hillmen, Steven Coutre, et al.
Blood Advances|April 4, 2022
Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemiaPaul M Barr, Carolyn Owen, Tadeusz Robak, et al.
Leukemia|October 20, 2019
Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 studyJan A Burger, Paul M Barr, Tadeusz Robak, et al.
Pageof 11